37 related articles for article (PubMed ID: 2842045)
1. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
[TBL] [Abstract][Full Text] [Related]
2. Biological clues to potent DNA-damaging activities in food and flavoring.
Hossain MZ; Gilbert SF; Patel K; Ghosh S; Bhunia AK; Kern SE
Food Chem Toxicol; 2013 May; 55():557-67. PubMed ID: 23402862
[TBL] [Abstract][Full Text] [Related]
3. Understanding Cancer's Defense against Topoisomerase-Active Drugs: A Comprehensive Review.
Sharma NK; Bahot A; Sekar G; Bansode M; Khunteta K; Sonar PV; Hebale A; Salokhe V; Sinha BK
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398072
[TBL] [Abstract][Full Text] [Related]
4. Modulation of selenium-dependent glutathione peroxidase activity enhances doxorubicin-induced apoptosis, tumour cell killing and hydroxyl radical production in human NCI/ADR-RES cancer cells despite high-level P-glycoprotein expression.
Doroshow JH; Juhasz A
Free Radic Res; 2019 Aug; 53(8):882-891. PubMed ID: 31290351
[TBL] [Abstract][Full Text] [Related]
5. Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer.
Mishra AK; Dormi SS; Turchi AM; Woods DS; Turchi JJ
Biochem Pharmacol; 2015 Jan; 93(1):25-33. PubMed ID: 25449597
[TBL] [Abstract][Full Text] [Related]
6. Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival.
Rezano A; Kuwahara K; Yamamoto-Ibusuki M; Kitabatake M; Moolthiya P; Phimsen S; Suda T; Tone S; Yamamoto Y; Iwase H; Sakaguchi N
BMC Cancer; 2013 Dec; 13():562. PubMed ID: 24289229
[TBL] [Abstract][Full Text] [Related]
7. Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.
Sinha BK; Kumar A; Bhattacharjee S; Espey MG; Mason RP
J Pharmacol Exp Ther; 2013 Dec; 347(3):607-14. PubMed ID: 24049059
[TBL] [Abstract][Full Text] [Related]
8. Integrative genomics: quantifying significance of phenotype-genotype relationships from multiple sources of high-throughput data.
Gamazon ER; Huang RS; Dolan ME; Cox NJ; Im HK
Front Genet; 2012; 3():202. PubMed ID: 23755062
[TBL] [Abstract][Full Text] [Related]
9. Role of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16,213).
Sinha BK; Bhattacharjee S; Chatterjee S; Jiang J; Motten AG; Kumar A; Espey MG; Mason RP
Chem Res Toxicol; 2013 Mar; 26(3):379-87. PubMed ID: 23402364
[TBL] [Abstract][Full Text] [Related]
10. Persistence of DNA damage following exposure of human bladder cells to chronic monomethylarsonous acid.
Wnek SM; Medeiros MK; Eblin KE; Gandolfi AJ
Toxicol Appl Pharmacol; 2009 Dec; 241(2):202-9. PubMed ID: 19699219
[TBL] [Abstract][Full Text] [Related]
11. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity.
Huang RS; Duan S; Bleibel WK; Kistner EO; Zhang W; Clark TA; Chen TX; Schweitzer AC; Blume JE; Cox NJ; Dolan ME
Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9758-63. PubMed ID: 17537913
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human topoisomerase II by anti-neoplastic benzazolo[3,2-alpha]quinolinium chlorides.
Vivas-Mejía PE; Cox O; González FA
Mol Cell Biochem; 1998 Jan; 178(1-2):203-12. PubMed ID: 9546601
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.
Pommier Y
Cancer Chemother Pharmacol; 1993; 32(2):103-8. PubMed ID: 8387398
[No Abstract] [Full Text] [Related]
14. Circumvention of atypical multidrug resistance with tumor necrosis factor.
Cimoli G; Valenti M; Parodi S; De Sessa F; Russo P
Jpn J Cancer Res; 1994 Feb; 85(2):135-8. PubMed ID: 8144394
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to combinations of vincristine, etoposide and doxorubicin in Chinese hamster ovary cells.
Souès S; Laval F; Charcosset JY
Br J Cancer; 1995 Mar; 71(3):489-97. PubMed ID: 7880729
[TBL] [Abstract][Full Text] [Related]
16. Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.
Hill BT
Cytotechnology; 1993; 12(1-3):265-88. PubMed ID: 7765329
[TBL] [Abstract][Full Text] [Related]
17. "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).
Cimoli G; Valenti M; Noviello E; Parodi S; Mazzoni A; Rovini E; De Sessa F; Russo P
J Cancer Res Clin Oncol; 1995; 121(3):155-63. PubMed ID: 7713987
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
Sinha BK
Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211
[TBL] [Abstract][Full Text] [Related]
19. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.
Henwood JM; Brogden RN
Drugs; 1990 Mar; 39(3):438-90. PubMed ID: 2184009
[No Abstract] [Full Text] [Related]
20. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Bugg BY; Danks MK; Beck WT; Suttle DP
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
